The FDA has approved Alnylam Pharmaceuticals' Onpattro, or patisiran, for the treatment of polyneuropathy in patients with hereditary ATTR amyloidosis, making it the first gene-silencing drug to win US approval. Onpattro will carry an annual list price of $450,000 for the average patient, and several insurers, including Harvard Pilgrim Health Care, agreed to cover the drug through value-based deals with Alnylam.
FDA OKs first gene-silencing drug for polyneuropathy of hATTR amyloidosis
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.